SV Angel, one of
the Valley’s best-known early-stage firms, says it’s starting to look
heavily at health startups that take a “software-first approach” towards
human biology, medical research and patient care.
The firm has always had a list of six to eight “megatrends” that it
invests prolifically in. Right now, those are big data, social commerce,
online-to-offline commerce, education tech, the sharing economy and the
“Internet of things.” Now they’re adding “health informatics” to that
list.
By that, SV Angel is looking for startups that “use software, IT and
data science to help diagnose, treat, reduce and cure disease – at the
physical, mental and emotional levels.” It’s a broader definition than
just bioinformatics, because it encompasses medical records and other
types of patient data.
Managing director David Lee, who is a cancer survivor, said that the firm finally feels comfortable with the idea that software is about to eat healthcare.
“I’m not a biologist. I don’t invest in biotech companies. We’re
software investors first and foremost,” he said. “But the more I learned
about bioinformatics and health records, the more I felt that the
timing was ripe.”
A couple things are feeding into this. For one, the costs of genome
sequencing are falling dramatically. The cost of sequencing a full human
genome has gone from $100 million in 2001 to $8,000 today — even faster
than Moore’s Law. Secondly, there are meaningful governmental and
financial incentives to move toward electronic medical records. (It’s
also just common sense to move away from paper records.)
He pointed to investments in companies like Counsyl (which I profiled earlier this week),
Benchling and medical records startups like Elation EMR and Practice
Fusion. There are also younger startups like Medisas, which is building
software to help with patient hand-offs and transfers.
A few other firms like Founders Fund, Khosla Ventures and Felicis
Ventures have carved out reputations over the past few years for
aggressively investing in health tech. Note that no one here is backing
companies that require an expensive, 10-year drug testing cycle overseen
by the FDA. All of these firms tend to look for companies that have
less regulatory risk, like in the medical devices space or with
diagnostics and bioinformatics (although Founders Fund has done a few
deals in FDA-regulated therapeutic biotechnology if they felt
comfortable with the team and opportunity).
SV Angel has been one of the most prolific backers of social networking, real-time, mobile (and yes, even SoLoMo) startups over the past few years. So are they eating their words?
“People might say that consumer’s not hot again, but we’re still
going to invest in consumer startups,” Lee said. “We don’t try to time
the market.”
Lee explained the firm’s thinking behind its new focus in a blog post today:
We at SV Angel invest in “megatrends.” We pick 4-6
investment themes and invest heavily in each one. Some of these trends
include: real-time data, online-to-offline consumption, social commerce,
collaborative consumption, education and the internet of things.
We believe that there is a massive opportunity in the intersection of
software and biology, which we broadly define as “Health Informatics.”
This term has a formal definition but we tweaked it to make our own. It
is a software-first approach to solving problems in human biology,
medical research and ultimately, patient care. We think the timing is
right for software developers to make an impact in these areas. The
ultimate goal is to use software, IT and data science to help diagnose,
treat, reduce and cure disease – at the physical, mental and emotional
levels. If we see a bright founder working in this area, the opportunity
will move to the “top of the pile” as if it’s in one of our other
preferred trends.
The catalyst of this trend is the cheap, abundant data of two types –
medical and molecular data. Cheap, abundant data combined with new ways
of measurement and analysis leads to technological breakthroughs. There
will be a flood of medical data driven by electronic medical records
and the like. For example, the recentAffordable Care Act (i.e.,
“Obamacare”) basically pays doctors for complying with a federal mandate
to move from paper to software-based solutions. By 2024 or so, every
hospital will move to electronic records. Right now, it’s estimated that
only 2% of hospitals comply with this law. Thus in ten years, the
amount of data will increase 50X.
On the molecular front, the costs of sequencing technology is falling
almost 5x faster than Moore’s Law. (The interpretation and analysis of
the data lags this trend but is improving as well.) President Obama also
recently announced a major national initiative to map the human brain
in the same way that human genome was mapped back in the early 1990′s.
This is just another example of “offline” or analog data being digitized
and accessible to coders.
Google motivated a generation of bright computer scientists to learn
the ins-and-outs of the advertising industry and turn it into a software
problem. The original PayPal founding team went through the schlep work
of learning the norms, regulations and other vagaries of the payment
industry in the early 2000′s. And they used software to help re-invent
it. And most recently, Palantir went through the hard, unsexy work of
understanding the intelligence and defense industries and used software
to attack hard, important problems. We want to back founders who want to
do the same when it comes to health informatics.
We are already working with and investors in founders and companies
in this area. Those include Counsyl, Benchling, Practice Fusion,
ElationEMR, DNA Nexus, Medisas and Flatiron. Counsyl in particular is a
flagship company. They were featured yesterday inTechCrunch. The
founding team has a traditional computer science background. In fact,
they even started the company thinking they were going to be a pure
software shop. Ultimately, they built a lab using cheap, commodotized
hardware – a trend that wasn’t in vogue then but is now. Ramji
Srinivasan, the CEO of Counsyl, is the archetype of what we will look
for. He will be an advisor to us on this effort.
Another advisor is Professor Atul Butte, a Stanford University School
of Medicine professor, researcher and entrepreneur in medical
bionformatics. He has been a thought leader and pioneer in the area of
applying computer and data science to biomedical research. He is a
sounding board and inspiration for us to pursue this trend and we’re
thrilled to have him with us as we learn more about this fascinating
area.
But perhaps the most critical advisors to us will be Jeremy Richman
and Jennifer Hensel. They are scientists and lost their only child,
Avielle, in the Newtown shooting. They courageously set up the [Avielle
Foundation}(http://aviellefoundation.org/)
to use science and technology to help understand why these tragedies
happen. They encouraged us to think more holistically about how to
reduce gun violence and how to use technology to identify and treat the
root causes of these tragedies. Biomedical research, bioinformatics and
brain health are all areas that need further investigation to understand
the “why” as well as the “how.” Great software companies and
entrepreneurs can play a fundamental role here.
On a personal front, I am a cancer survivor so I have a selfish
reason to accelerate this vision. Scientists are more confident than
ever that genetic mutations play a huge role in why cancer happens. I
believe that great software companies in the mold of Google, PayPal and
Palantir will help make cancer a chronic condition and quite possibly,
cured.
To be clear, while this megatrend has philanthropic and personal
benefits, this is not a philanthropic or personal venture. We believe
this is a massive market opportunity for young hackers and founders. And
we want to be crystal clear that this effort is consistent with our
historical focus – great founders using software to address new and
large markets.
Post a Comment
Thanks for reading my blog.
Note: only a member of this blog may post a comment.